TNF and inflammatory bowel disease: Inflammation is a key player in IBD and several assessments have highlighted that anti‐TNF monoclonal antibodies, namely, infliximab and adalimumab, are effective therapeutic options in inducing remission in moderate to severe IBD by downregulating several pro‐inflammatory mediators (Cavallaro et al., 2017).